Brief: Timber Pharma Gets Orphan Drug Designation From FDA For Tmb-003 For Treatment Of Systemic Sclerosis

Trex Wind-Down

12/01/2021 21:57

Jan 12 (Reuters) - Timber Pharmaceuticals Inc  TMBR.A :
    * TIMBER PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION
FROM
U.S. FDA FOR TMB-003 FOR THE TREATMENT OF SYSTEMIC SCLEROSIS
    * TIMBER PHARMACEUTICALS INC - EXPECTS TO SUBMIT
INVESTIGATIONAL
NEW DRUG (IND) APPLICATION TO FDA IN 2022

Source text for Eikon:  ID:nGNE9TKsYN 
Further company coverage:  TMBR.A 

 ((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))